“Pityriasis Rubra Pilaris, Refractory to IL-17A Inhibition, with Rapid Improvement Following IL-17A/IL-17F Blockade by Bimekizumab” (2024) SKIN The Journal of Cutaneous Medicine, 8(6), pp. 1987–1992. doi:10.25251/skin.8.6.13.